SynthesisHypertension (Dallas, Tex. : 1979)2016
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.
Open access · bronzeAbstract readMeta-Analysis
In one paragraph
Synthesis in Hypertension (Dallas, Tex. : 1979), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Genome-Wide Meta-Analysis of Blood Pressure Response to βJournal of the American Heart Association · 2019Pooled it
- Genome Wide Association Study Identifies theJournal of the American Heart Association · 2018Pooled it
- Pharmacogenetic and microRNA mechanisms of beta blocker use on bone.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Trial
- Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.Clinical and translational science · 2019Trial
- A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).Clinical pharmacology and therapeutics · 2019Trial
- Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).Circulation. Genomic and precision medicine · 2018Trial
- Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review.Journal of clinical medicine · 2023Review
- Leveraging drug perturbation to reveal genetic regulators of hepatic gene expression in African Americans.American journal of human genetics · 2023Article
- Genetic heterogeneity in cardiovascular disease across ancestries: Insights for mechanisms and therapeutic intervention.Cambridge prisms. Precision medicine · 2023Review
- Pharmacogenomics of Hypertension in Africa: Paving the Way for a Pharmacogenetic-Based Approach for the Treatment of Hypertension in Africans.International journal of hypertension · 2023Review
- Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients.Metabolites · 2022Article
- Pharmacogenomic Effects of β-Blocker Use on Femoral Neck Bone Mineral Density.Journal of the Endocrine Society · 2021Article
- Pharmacological approaches to the treatment of COVID-19 patients.Journal of translational science · 2020Article
- Pharmacogenomics of Hypertension Treatment.International journal of molecular sciences · 2020Review
- Relationship between a Weighted Multi-Gene Algorithm and Blood Pressure Control in Hypertension.Journal of clinical medicine · 2019Article
- Leaving some behind: the growing gap in precision medicine for minority populations.Expert review of precision medicine and drug development · 2019Article
- The Effect of Genetically Guided Mathematical Prediction and the Blood Pressure Response to Pharmacotherapy in Hypertension Patients.Clinical Medicine Insights. Cardiology · 2019Article
- Article
- Pharmacogenomics And Hypertension: Current Insights.Pharmacogenomics and personalized medicine · 2019Review
- Hypertension genomics and cardiovascular prevention.Annals of translational medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Yan GongFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.). gong@cop.ufl.edu.
Zhiying WangFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Amber L BeitelsheesFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Caitrin W McDonoughFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Taimour Y LangaeeFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Karen HallFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Siegfried O F SchmidtFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Robert W CurryFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
John G GumsFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Kent R BaileyFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Eric BoerwinkleFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Arlene B ChapmanFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Stephen T TurnerFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Rhonda M Cooper-DeHoffFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
Julie A JohnsonFrom the Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., C.W.M., T.Y.L., J.G.G., R.M.C.-D., J.A.J.), Department of Community Health and Family Medicine, College of Medicine (K.H., S.O.F.S., R.W.C., J.G.G.), and Division of Cardiovascular Medicine, College of Medicine (R.M.C.-D., J.A.J.), University of Florida, Gainesville; Department of Epidemiology, Human Genetics & Environmental Sciences, Center for Human Genetics, University of Texas Health Science Center at Houston (Z.W., E.B.); Department of Medicine and Program in Personalized & Genomic Medicine, University of Maryland, Baltimore (A.L.B.); Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.B.) and Division of Nephrology and Hypertension (S.T.T.), Mayo Clinic, Rochester, MN; and Department of Medicine, University of Chicago, IL. (A.B.C.).
University of Maryland, Baltimore · USCenter for Human Genetics · USMayo Clinic in Florida · US
Funding
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2MUsing social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2MAtlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8MPharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7MRe-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2MUF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2MNCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR000430NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR001427NIGMS NIH HHS U01 GM074492NIGMS NIH HHS U01-GM074492
Abstract
African Americans suffer a higher prevalence of hypertension compared with other racial/ethnic groups. In this study, we performed a pharmacogenomic genome-wide association study of blood pressure (BP) response to β-blockers in African Americans with uncomplicated hypertension. Genome-wide meta-analysis was performed in 318 African American hypertensive participants in the 2 Pharmacogenomic Evaluation of Antihypertensive Responses studies: 150 treated with atenolol monotherapy and 168 treated with metoprolol monotherapy. The analysis adjusted for age, sex, baseline BP and principal components for ancestry. Genome-wide significant variants with P<5×10(-8) and suggestive variants with P<5×10(-7) were evaluated in an additional cohort of 141 African Americans treated with the addition of atenolol to hydrochlorothiazide treatment. The validated variants were then meta-analyzed in these 3 groups of African Americans. Two variants discovered in the monotherapy meta-analysis were validated in the add-on therapy. African American participants heterozygous for SLC25A31 rs201279313 deletion versus wild-type genotype had better diastolic BP response to atenolol monotherapy, metoprolol monotherapy, and atenolol add-on therapy: -9.3 versus -4.6, -9.6 versus -4.8, and -9.7 versus -6.4 mm Hg, respectively (3-group meta-analysis P=2.5×10(-8), β=-4.42 mm Hg per variant allele). Similarly, LRRC15 rs11313667 was validated for systolic BP response to β-blocker therapy with 3-group meta-analysis P=7.2×10(-8) and β=-3.65 mm Hg per variant allele. In this first pharmacogenomic genome-wide meta-analysis of BP response to β-blockers in African Americans, we identified novel variants that may provide valuable information for personalized antihypertensive treatment in this group.
Indexed as
Black or African AmericanHypertensionAdrenergic beta-AntagonistsBlood PressureGenome-Wide Association StudyHumansMorbidityPharmacogeneticsUnited StatesAdrenergic beta-AntagonistsAfrican Americansblood pressure responseGWASPEARpharmacogenomicsβ-blockers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.